NextPlat Corp (NASDAQ: NXPL, NXPLW) announced an agreement to acquire an independent pharmacy in a rural community near Pensacola, Florida, for $1.5 million in cash, with the transaction expected to close during the fourth quarter of 2026, subject to customary closing conditions. The acquisition will expand the company’s PharmcoRx retail footprint into an underserved market, where it plans to introduce same-day delivery, online fulfillment and higher-margin contracted services, including support for healthcare providers participating in the federal 340B Drug Pricing Program, long-term care facilities and government agencies.
The pharmacy generated approximately $5.6 million in sales during 2025 with retail margins of about 19% and operated profitably with positive working capital and no debt. NextPlat said the acquisition supports its strategy of expanding healthcare operations through rural pharmacy acquisitions, building on PharmcoRx’s existing network of four specialty pharmacies in Florida and the healthcare segment’s $39.7 million contribution to the company’s $54.3 million in 2025 revenue.
This acquisition is significant because it positions NextPlat to capitalize on the growing demand for pharmacy services in rural areas, which often face limited access to healthcare. By adding same-day delivery and online fulfillment, the company can enhance patient convenience and adherence to medications. Moreover, the focus on the 340B Drug Pricing Program allows NextPlat to partner with covered entities to provide discounted drugs to low-income and uninsured patients, a key driver of higher-margin revenue. The acquisition also aligns with NextPlat’s broader strategy to diversify its revenue streams beyond e-commerce and technology solutions, which include voice, data, and IoT products.
The deal underscores NextPlat’s commitment to building a scalable pharmacy network through targeted acquisitions. With the healthcare segment already contributing $39.7 million to total 2025 revenue of $54.3 million, this acquisition could further boost profitability. The target pharmacy’s strong financials—$5.6 million in sales, 19% margins, and no debt—indicate a low-risk addition that can be integrated quickly. Investors should watch for the closing in Q4 2026 and subsequent performance updates.
For more details, see the full press release at https://nnw.fm/8bVkW and the latest news on NXPL at https://nnw.fm/NXPL.
